The global joint pain injections market size accounted for USD 6.03 billion in 2025 and is projected to surpass around USD 10.73 billion by 2034, representing a healthy CAGR of 6.61% between 2025 and 2034. The North America joint pain injections market size surpassed USD 2.60 billion in 2024 and is expanding at a CAGR of 6.63% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Joint Pain Injections Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Joint Pain Injections Market, by Product Type
8.1.1. Pre-filled injections
8.1.1.1. Market Revenue and Forecast
8.1.2. Vials
8.1.2.1. Market Revenue and Forecast
9.1. Joint Pain Injections Market, by Injection
9.1.1. Corticosteroid Injections
9.1.1.1. Market Revenue and Forecast
9.1.2. Hyaluronic Acid Injections
9.1.2.1. Market Revenue and Forecast
9.1.3. Platelet-rich Plasma Injections
9.1.3.1. Market Revenue and Forecast
9.1.4. Placental tissue matrix (PTM) Injections
9.1.4.1. Market Revenue and Forecast
10.1. Joint Pain Injections Market, by Joint Type
10.1.1. Knee and Ankle
10.1.1.1. Market Revenue and Forecast
10.1.2. Hip
10.1.2.1. Market Revenue and Forecast
10.1.3. Shoulder and Elbow
10.1.3.1. Market Revenue and Forecast
10.1.4. Spinal Joints
10.1.4.1. Market Revenue and Forecast
10.1.5. Others
10.1.5.1. Market Revenue and Forecast
11.1. Joint Pain Injections Market, by Distribution Type
11.1.1. Hospital Pharmacies
11.1.1.1. Market Revenue and Forecast
11.1.2. Retail Pharmacies
11.1.2.1. Market Revenue and Forecast
11.1.3. Online Pharmacies
11.1.3.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Product
12.1.2. Market Revenue and Forecast, by Injection
12.1.3. Market Revenue and Forecast, by Joint Type
12.1.4. Market Revenue and Forecast, by Distribution Type
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product
12.1.5.2. Market Revenue and Forecast, by Injection
12.1.5.3. Market Revenue and Forecast, by Joint Type
12.1.5.4. Market Revenue and Forecast, by Distribution Type
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product
12.1.6.2. Market Revenue and Forecast, by Injection
12.1.6.3. Market Revenue and Forecast, by Joint Type
12.1.6.4. Market Revenue and Forecast, by Distribution Type
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product
12.2.2. Market Revenue and Forecast, by Injection
12.2.3. Market Revenue and Forecast, by Joint Type
12.2.4. Market Revenue and Forecast, by Distribution Type
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product
12.2.5.2. Market Revenue and Forecast, by Injection
12.2.5.3. Market Revenue and Forecast, by Joint Type
12.2.5.4. Market Revenue and Forecast, by Distribution Type
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product
12.2.6.2. Market Revenue and Forecast, by Injection
12.2.6.3. Market Revenue and Forecast, by Joint Type
12.2.6.4. Market Revenue and Forecast, by Distribution Type
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product
12.2.7.2. Market Revenue and Forecast, by Injection
12.2.7.3. Market Revenue and Forecast, by Joint Type
12.2.7.4. Market Revenue and Forecast, by Distribution Type
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product
12.2.8.2. Market Revenue and Forecast, by Injection
12.2.8.3. Market Revenue and Forecast, by Joint Type
12.2.8.4. Market Revenue and Forecast, by Distribution Type
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product
12.3.2. Market Revenue and Forecast, by Injection
12.3.3. Market Revenue and Forecast, by Joint Type
12.3.4. Market Revenue and Forecast, by Distribution Type
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product
12.3.5.2. Market Revenue and Forecast, by Injection
12.3.5.3. Market Revenue and Forecast, by Joint Type
12.3.5.4. Market Revenue and Forecast, by Distribution Type
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product
12.3.6.2. Market Revenue and Forecast, by Injection
12.3.6.3. Market Revenue and Forecast, by Joint Type
12.3.6.4. Market Revenue and Forecast, by Distribution Type
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product
12.3.7.2. Market Revenue and Forecast, by Injection
12.3.7.3. Market Revenue and Forecast, by Joint Type
12.3.7.4. Market Revenue and Forecast, by Distribution Type
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product
12.3.8.2. Market Revenue and Forecast, by Injection
12.3.8.3. Market Revenue and Forecast, by Joint Type
12.3.8.4. Market Revenue and Forecast, by Distribution Type
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product
12.4.2. Market Revenue and Forecast, by Injection
12.4.3. Market Revenue and Forecast, by Joint Type
12.4.4. Market Revenue and Forecast, by Distribution Type
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product
12.4.5.2. Market Revenue and Forecast, by Injection
12.4.5.3. Market Revenue and Forecast, by Joint Type
12.4.5.4. Market Revenue and Forecast, by Distribution Type
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product
12.4.6.2. Market Revenue and Forecast, by Injection
12.4.6.3. Market Revenue and Forecast, by Joint Type
12.4.6.4. Market Revenue and Forecast, by Distribution Type
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product
12.4.7.2. Market Revenue and Forecast, by Injection
12.4.7.3. Market Revenue and Forecast, by Joint Type
12.4.7.4. Market Revenue and Forecast, by Distribution Type
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product
12.4.8.2. Market Revenue and Forecast, by Injection
12.4.8.3. Market Revenue and Forecast, by Joint Type
12.4.8.4. Market Revenue and Forecast, by Distribution Type
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product
12.5.2. Market Revenue and Forecast, by Injection
12.5.3. Market Revenue and Forecast, by Joint Type
12.5.4. Market Revenue and Forecast, by Distribution Type
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product
12.5.5.2. Market Revenue and Forecast, by Injection
12.5.5.3. Market Revenue and Forecast, by Joint Type
12.5.5.4. Market Revenue and Forecast, by Distribution Type
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product
12.5.6.2. Market Revenue and Forecast, by Injection
12.5.6.3. Market Revenue and Forecast, by Joint Type
12.5.6.4. Market Revenue and Forecast, by Distribution Type
13.1. Online Pharmacies
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Bioventus
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Ferring Pharmaceuticals Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Sanofi
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Zimmer Biomet Holdings Inc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Allergen Plc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Pfizer Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Chugai Pharmaceutical Co. Ltd
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. SEIKAGAKU Corporation
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Ferring B.V.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description